Technology in Cancer Research & Treatment最新文献

{"title":"CGRP, PD-1 and PD-L1 as Biomarkers for PICC-Related Bloodstream Infections in Breast Cancer Patients.","authors":"Jun-Tao Tan, Lili Hu, Qi-Hua Jiang, Hai Hu, Zhi Yang, Zhi-Hua Li, Ping-Hua Hu","doi":"10.1177/15330338251342877","DOIUrl":"10.1177/15330338251342877","url":null,"abstract":"<p><p>IntroductionPeripherally inserted central catheter (PICC)-related bloodstream infections (BSIs) are severe complications in breast cancer patients undergoing chemotherapy. This study evaluated the diagnostic potential of calcitonin gene-related peptide (CGRP), programmed cell death protein-1 (PD-1), and its ligand (PD-L1) as biomarkers for PICC-related BSIs.MethodsA total of 384 breast cancer patients with PICC placement were retrospectively identified from medical records, of these, 78 developed BSIs and 306 did not. Serum levels of CGRP, PD-1, and PD-L1 were measured using enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR), respectively, to evaluate their potential as diagnostic biomarkers for BSIs. Blood cultures were performed to confirm infections and identify pathogens.ResultsThe BSIs group showed significantly lower CGRP and PD-L1 levels, and higher PD-1 expression and PD-1/PD-L1 ratios compared to the non-BSIs group (all P < 0.001). Receiver operating characteristic (ROC) curve analysis showed area under the curve (AUC) values of 0.84 for CGRP, 0.77 for PD-1, 0.70 for PD-L1, and 0.86 for the PD-1/PD-L1 ratio. Combined detection achieved an AUC of 0.96, with 88% sensitivity and 92% specificity. Gram-negative bacteria (59.8%) were the predominant pathogens, with Escherichia coli (29.3%) being the most common.ConclusionCGRP alone showed strong diagnostic utility, but combining CGRP, PD-1, and PD-L1 markedly enhanced accuracy. ELISA and qPCR detection of these markers provides results within hours, enabling earlier diagnosis than conventional blood cultures.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251342877"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time Matters: A Review of Current Radiotherapy Practices and Efficiency Strategies.","authors":"Sibel Karaca, Meltem Kırlı Bölükbaş","doi":"10.1177/15330338251345376","DOIUrl":"10.1177/15330338251345376","url":null,"abstract":"<p><p>Radiotherapy is a multi-step process that includes planning, contouring, simulation, patient assessment, quality control, and treatment. Each step must be completed before moving on to the next. Numerous factors, including patient characteristics, disease type, management, radiotherapy personnel, equipment, treatment modality, and total/fractional doses, affect the overall duration of radiotherapy. Time is one of life's most valuable resources and should be well managed and utilized. In radiotherapy, eliminating factors that unnecessarily prolong the treatment period significantly benefits the institution, patient, and staff. This review article examines the variables that affect overall treatment time in current external beam radiotherapy routines and offers suggestions for reducing treatment time.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251345376"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemotherapy for Anorectal Tumors: A Narrative Literature Review.","authors":"Martina Ferioli, Alessandra Arcelli, Savino Cilla, Arina A Zamfir, Giorgio Tolento, Dajana Cuicchi, Milly Buwenge, Erika Galietta, Bruno Fionda, Luca Tagliaferri, Matteo Rottoli, Gilberto Poggioli, Alessio G Morganti","doi":"10.1177/15330338251349596","DOIUrl":"10.1177/15330338251349596","url":null,"abstract":"<p><p>This narrative review explores the potential role of electrochemotherapy (ECT) in treating anorectal tumors, focusing on its effectiveness, feasibility, and associated toxicities. ECT, which combines chemotherapy with the application of an electric field to enhance drug uptake by tumor cells, has shown promise as a local treatment, particularly in cases where conventional therapies such as radiotherapy have been exhausted or are unsuitable. The review, conducted according to SANRA guidelines, included 18 studies, on ECT in anorectal tumors, ranging from preclinical trials in dogs to case reports and clinical studies in humans. The findings indicate that ECT can achieve high tumor overall response rates (70-100%) with minimal side effects, offering benefits such as tumor reduction and preserved organ function. These results highlight the potential of ECT to provide not only tumor reduction but also the preservation of vital organ function with a relatively low toxicity profile. However, further comparative research is necessary to substantiate its role as a standard therapeutic option. Moreover, the evidence is limited by significant heterogeneity across studies, small sample sizes, and a lack of comparative research with other local treatments like radiotherapy and cryosurgery. Consequently, while ECT appears to be a promising option, particularly for palliative care or in a neoadjuvant setting, it cannot yet be recommended as a standard treatment. Future research should focus on larger, more robust studies with standardized outcomes and explore the potential synergy between ECT and other therapies to establish its place in the treatment of anorectal tumors.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251349596"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical Cancer in Pregnancy: A 10-Year Retrospective Analysis of Clinical Management and Future Perspectives.","authors":"Yuliang Sun, Weishi Cheng, Jing Shen, Hongnan Zhen, Hui Guan, Lei He, Ke Hu, Fuquan Zhang, Zhikai Liu","doi":"10.1177/15330338251356924","DOIUrl":"10.1177/15330338251356924","url":null,"abstract":"<p><p>IntroductionThis study aims to evaluate diagnosis, treatment and clinical outcomes for patients with cervical cancer in pregnancy (CCIP) and their fetuses over a 10-year period, providing clinical evidence for the management of CCIP.MethodsClinical data of 28 patients diagnosed with CCIP at our center between January 1st, 2013 and June 30th, 2023 were retrospectively analyzed, focusing on gestational age at diagnosis, treatment, and maternal-fetal outcomes.ResultsA total of 28 patients with CCIP were identified, accounting for 0.42% (28/6678) of patients with cervical cancer during the study period. The majority of patients (86%, 24/28) had squamous cell carcinoma diagnosed by colposcopic biopsy, and 21 patients presented with recurrent vaginal bleeding. Cervical cancer was diagnosed during pregnancy in 19 cases and in the postpartum period in 9 cases. The mean tumor diameter was 5.4 (2-12) cm. Among 19 patients diagnosed during pregnancy, 13 patients chose pregnancy preservation, resulting in an average delay of treatment by 16.4 (0-33) weeks without observed disease progression. Fetuses were delivered via cesarean section at an average gestational age of 36.3 weeks; eight of these patients received neoadjuvant chemotherapy. At a median follow-up duration of 40.1 (12-103) months, 25 patients survived. Disease-free survival was observed in 20 patients, whereas two patients experienced local progression, and six developed distant metastases.ConclusionClinical outcomes for patients with CCIP appear comparable to those observed in non-pregnant patients in the general population. Pregnant patients presenting with abnormal vaginal bleeding should undergo prompt cervical cancer screening to enable early diagnosis and tailored management strategies. For patients with a strong desire to maintain their pregnancy, careful consideration should be given to postponing delivery until fetal maturity, thereby minimizing maternal and fetal complications and improving maternal and fetal outcomes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251356924"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma.","authors":"Michele Maffezzoli, Alessio Signori, Davide Campobasso, Giulia Claire Giudice, Nicola Simoni, Massimo De Filippo, Enrico Maria Silini, Sebastiano Buti","doi":"10.1177/15330338251329848","DOIUrl":"10.1177/15330338251329848","url":null,"abstract":"<p><p>IntroductionStratifying the risk of recurrence for surgically treated papillary renal cell carcinoma (pRCC) could be challenging. Prognostic models are crucial for patient counselling and individualized surveillance. The GRANT score is one of the models suggested by guidelines to predict prognosis of surgically treated pRCC. This study aims to externally validate the GRANT score using a three-risk group stratification in a large cohort of pRCC patients.Materials and MethodsThe present analysis utilized retrospective data from pRCC patients who underwent radical or partial nephrectomy. The GRANT score parameters included tumor grade, age, pathological T-stage, and N-stage. Patients were stratified into three risk groups (0-1 vs 2 vs 3-4 risk factors). Cancer-specific survival (CSS) was assessed using the Kaplan-Meier method, and differences between groups were evaluated using the log-rank test. Harrell's c-index was used to measure model accuracy, and restricted mean survival time (RMST) was calculated for up to 120 months.ResultsA total of 1942 patients were included. The median follow-up was 64.6 months. At 60 months, CSS was 93.2% (95%CI 91.7%-94.6%) for group 1, 60.8% (95%CI 54.0%-78.6%) for group 2, and 26% (95%CI 15.7%-42.9%) for group 3, with significant differences between each group (p < 0.001). The median CSS was not reached for group 1 (95%CI NR-NR), 86.0 months in group 2 (95%CI 65-NR), and 22.8 months in group 3 (95%CI 16.4-48.0). The c-index for CSS was 0.732. The RMST at 120 months was 113.3 months for group 1, 75.9 months for group 2, and 56.6 months for group 3, with a statistically significant difference (p < 0.001).ConclusionThe GRANT score effectively stratified surgically treated pRCC patients into three risk groups, demonstrating good prognostic accuracy. This validation supports the GRANT score's utility as a reliable and easy-to-use prognostic tool.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251329848"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy Analysis of Hypofractionated Radiotherapy for Oligometastatic Tumors: A Retrospective Study.","authors":"Qian Sun, Hanqing Zhao, Xianwen Zhang, Suli Zhang, Zelai He, Gengming Wang, Hao Jiang, Aili Xuan, Xianming Li","doi":"10.1177/15330338241310155","DOIUrl":"10.1177/15330338241310155","url":null,"abstract":"<p><strong>Introduction: </strong>Metastasis remains a major cause of death among patients with malignant tumors. Radiotherapy is one of the main modalities of cancer treatment. The rapid development of radiotherapy technology has enabled the widespread application of hypofractionated radiotherapy (HFRT) in clinical practice. This study aimed to evaluate the effect of HFRT on the survival and safety of patients with oligometastatic tumors.</p><p><strong>Methods: </strong>We conducted a retrospective study that involved 65 patients with well-controlled primary tumors and 1-5 metastatic foci treated at the study site between January 2020 and December 2022. Patients were aged >18 years and had a ≥ 6-month life expectancy. The patients received standard treatments plus HFRT for all metastatic foci. The dose fractionation regimen was adjusted according to the location and size of the patient's metastatic foci. The planning gross tumor volume of HFRT was 82.93 cm³ (range: 10.12-562.80 cm³), and the radiation dose range was 20 Gy/5 F-60 Gy/15 F. Progression-free survival (PFS), overall survival (OS), local control rates, and incidence of adverse events of the patients were observed.</p><p><strong>Results: </strong>Among the 65 patients, the median follow-up time, PFS, and OS were 26 months (95% CI: 0.80-37.50), 15 months (95% CI: 9.36-20.64), and 28 months (95% CI: 16.71-39.29), respectively. The 1- and 2-year PFS were 53.8% and 40.0%, respectively, while the 1- and 2-year OS rates were 73.8% and 56.9%, respectively. In total, 13.8%, 55.4%, 20.0%, and 13.8% of patients showed complete response, partial response, stable disease, and progressive disease, respectively. Four patients developed grade 3 or worse adverse events, and no treatment-related deaths occurred.</p><p><strong>Conclusions: </strong>HFRT showed favorable clinical efficacy and safety in patients with oligometastatic tumors, generally achieving a good OS rate. Further randomized trials should be conducted.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241310155"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular Volume Derived from Equilibrium CT for the Prediction of Survival Outcomes in Patients with Pancreatic Ductal Adenocarcinoma.","authors":"Ju Xiong, Yunfeng Lu, Haotian Liu, Mengchu Ji, Zhiwei Zhang, Yongmei Li, Hongwei Liang","doi":"10.1177/15330338251336032","DOIUrl":"https://doi.org/10.1177/15330338251336032","url":null,"abstract":"<p><p>ObjectiveTo assess the efficiency of extracellular volume (ECV) derived from equilibrium computed tomography (CT) in predicting recurrence-free survival (RFS) and overall survival (OS) after R0 resection of pancreatic ductal adenocarcinoma (PDAC).MethodsThis retrospective study included 83 patients who underwent CT and R0 resection between January 2016 and September 2023. The pattern of tumor recurrence and prognosis were recorded for each patient. Tumor recurrence was classified into three groups: isolated local recurrence group, distant recurrence group and censored group. The associations between the CT-ECV and clinicopathological features and recurrence pattern of PDAC were evaluated by chi-squared test. Multivariable Cox proportional-hazards models were conducted to evaluate the effects of clinical factors, CT features and CT-ECV on RFS and OS.ResultsThe median RFS and OS were 10.7 and 17.1 months, respectively. On multivariate analysis, the CT-ECV and adjacent organ invasion were found to be associated with RFS (HR, 0.968, <i>P</i> = .017; HR, 0.453; <i>P</i> = .006), and only the CT-ECV was an independent prognostic factor for OS (HR, 0.968; <i>P</i> = .022). Low CT-ECV group was significantly associated with elevated CA19-9, larger tumor size, G3 (tumor grade) and II/III (AJCC tumor stage) (<i>P</i> < .05). In the recurrence pattern analysis, the CT-ECV did not exhibit an association between local recurrence and non-local recurrence groups (<i>P</i> = .455), while patients in the low CT-ECV group were more inclined to experience distant recurrence after curative surgery (<i>P</i> = .037).ConclusionsCT-ECV determined by equilibrium contrast-enhanced CT was a useful imaging biomarker for predicting distant recurrence and survival in resectable PDAC patients, which may facilitate further risk stratification and personalized care.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251336032"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).","authors":"Ya-Nan Wang, Chao-Wei Zhang, Yu-Xuan Gao, Xue-Ling Ge","doi":"10.1177/15330338251321349","DOIUrl":"10.1177/15330338251321349","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a malignant hematological disease originating from plasma cells that remains incurable. Autologous stem cell transplantation (ASCT) is an important treatment method for MM. With the development of new drugs, the treatment of MM patients who meet the ASCT criteria has significantly improved, and the median survival time has increased by 8-10 years. The current treatment for MM patients who meet the ASCT criteria consists mainly of the following stages: induction therapy, stem cell collection, stem cell transplantation, and consolidation and maintenance therapy. Even today, long-term disease control remains the goal of MM treatment in clinical practice. In the era of new drugs, early ASCT still results in longer progression-free survival (PFS) and is currently the standard treatment method for young newly diagnosed multiple myeloma (NDMM) patients. Moreover, tandem transplantation can be considered for MM patients with high-risk cytogenetics. This review discusses mainly the role of ASCT in MM, the conditions for patient transplantation, the induction chemotherapy regimen before transplantation, the conditioning regimen, the timing of transplantation, and the effectiveness of tandem transplantation, including maintenance and salvage ASCT after transplantation.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251321349"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics-Based Machine Learning for Determining <i>MYCN</i> Amplification Status in Childhood Neuroblastoma: A Systematic Review and Meta-Analysis.","authors":"Haoru Wang, Yi Ji, Xin Chen, Ling He, Xiangming Fang, Jinhua Cai","doi":"10.1177/15330338251358324","DOIUrl":"10.1177/15330338251358324","url":null,"abstract":"<p><p>IntroductionThe <i>MYCN</i> oncogene promotes tumor cell proliferation in neuroblastoma, and its amplification is a well-established marker of poor prognosis. Radiomics-based approaches have shown promise in noninvasively determining <i>MYCN</i> amplification status; however, their diagnostic performance has varied significantly across studies. This systematic review and meta-analysis aimed to quantitatively evaluate the diagnostic accuracy of radiomics-based machine learning models for determining <i>MYCN</i> amplification in neuroblastoma and to critically assess the methodological quality of the included studies.MethodsA systematic search of articles published between January 1, 2000, and June 30, 2024, was conducted across PubMed, Embase, Web of Science, and the Cochrane Library. The articles focused on using radiomics to determine <i>MYCN</i> amplification in neuroblastoma. Methodological quality was assessed using the Radiomics Quality Score (RQS), METhodological RadiomICs Score (METRICS), and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tools. A meta-analysis of validation performance was performed on studies with Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis statement Type 2a or higher.ResultsNine studies with 851 patients were included, and seven studies with 217 patients in the validation set were eligible for meta-analysis. The RQS scores ranged from 10 to 16 (mean 12), and METRICS scores ranged from 28.8% to 78.4% (mean 59.7%). QUADAS-2 assessment indicated that most studies had a low or unclear risk of bias. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were 0.78, 0.92, 9.45, and 0.24, respectively. The area under the summary receiver operating characteristic curve was 0.94 (95% confidence interval: 0.91-0.95).ConclusionDespite variability in study design and bias risk, radiomics shows promise as a non-invasive method for detecting <i>MYCN</i> amplification in neuroblastoma. Further refinement and validation in multicenter studies with larger sample sizes are needed to enhance its clinical applicability.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251358324"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-Targeted Nanoliposome Therapy Activates Immune Response by Converting Cold to Hot Breast Tumors.","authors":"Quan Sun, Ying Zhu, Dongli Zhao, Lili Yang, Siyu Zhang, Changxin Huang","doi":"10.1177/15330338251356387","DOIUrl":"10.1177/15330338251356387","url":null,"abstract":"<p><p>IntroductionHER2-positive breast cancer, accounting for 15%-20% of cases, remains challenging due to therapy resistance and immunosuppressive \"cold tumor\" microenvironments. Current strategies combining immunotherapy with chemotherapy or radiotherapy often face toxicity limitations. To address this, we developed HER2-targeted nanoliposomes co-delivering viral peptides and the STING agonist diABZI, aiming to convert cold tumors into immunologically active \"hot tumors\" by enhancing antigen spreading and immune recognition.MethodsViral peptides with high Human Leukocyte Antigen-A2 affinity were selected using NetMHCpan-4.1/4.0 and incorporated into nanoliposomes via thin-film dispersion. Trastuzumab F(ab')₂ fragments were conjugated for HER2-specific targeting. Nanoliposomes were characterized for size, stability, encapsulation efficiency (HPLC), and in vitro release. Immune efficacy was assessed via ELISPOT, flow cytometry (CD3+/CD8+/NK cells), and TCR β sequencing in HER2⁺ SK-BR-3 and HER2^- MCF-7 cells. Cytotoxicity and cellular uptake were evaluated using CCK-8 assays and fluorescence imaging.ResultsThe nanoliposomes exhibited uniform size (∼70 nm), stability (5% size variation over 25 days), and high encapsulation efficiency (75.5% for peptides). Targeted delivery to SK-BR-3 cells peaked at 60 µL (<i>P</i> < .05), with sustained release of peptides (52% at 48 h) and diABZI (46.2%). In HER2⁺ cells, nanoliposomes synergistically enhanced IFN-γ (2.5-fold, <i>P</i> < .01) and granzyme B (3-fold, <i>P</i> < .05) secretion, overcoming antagonism seen with free agents. Flow cytometry revealed dominant CD8⁺ T-cell infiltration (50.9% vs 0.67% in controls) and expanded NK/NKT populations. TCR β sequencing showed increased clonotype diversity (60,915 vs 57 574 clones) and reduced clonal dominance, indicating broadened antigen recognition.ConclusionOur HER2-targeted nanoliposomes effectively reprogrammed cold tumors by dual activation of innate (STING pathway) and adaptive (viral peptide-driven TCR diversity) immunity. The platform demonstrated robust targeting, safety, and immune activation, offering a promising strategy to overcome immunotherapy resistance. Future studies will validate in vivo efficacy and explore adaptations for other cold tumors via alternative targeting ligands.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251356387"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}